Drug development under way with discovery of how to treat heart attack
Vanderbilt researchers have identified the protein receptor in specialized heart cells that, when removed, preserves cardiac function after a heart attack. This discovery has significant implications for survival after a heart attack, with a promising therapeutic development now underway at the Warren Center for Neuroscience Drug Discovery.
The research was led by David Merryman, a professor of biomedical engineering who holds the Walters Family Chair, with experiments conducted by Caleb Snider, a former Vanderbilt graduate student and current postdoctoral fellow at Washington University in St. Louis, and others. The team used genetic and drug models to confirm that removal of serotonin 2B receptors within cardiac fibroblasts—“worker bee” cells that produce connective tissue in the heart—help the organ heal significantly after a heart attack.
Typically, only a small region of the heart dies during a heart attack (myocardial infarction), but over time the borders of the scarred region expand. The resulting stress on the heart to do more with less induces heart failure. The researchers set out to precisely determine what the protein receptor did during heart attacks and how it might be altered for improved outcomes.
Heart health is measured by ejection fraction—how well the heart is pumping. Normally, an animal has an 80 percent ejection fraction, which decreases by half following a heart attack. In models in which serotonin 2B was either treated by a drug or genetically removed, the heart had a 50 percent greater ejection fraction six weeks after a heart attack than models in which serotonin 2B remained in cardiac fibroblasts, Merryman explained.
The biggest metric in this study was cardiac function, measured through echocardiography. Through biomechanical characterization of the scar and the adjacent border zone, the researchers measured changes in scar tissue structure and function. Early inhibition of serotonin 2B after a heart attack results in a functional scar that is less likely to expand beyond the initial wound to put additional pressure on the heart, they found.
“We found that the drug models have an acute and long-term effect,” Merryman said. “The drug treatment preserves cardiac function six weeks after a heart attack to a much greater extent than the control group, and it effectively contains the border zone of the affected area of the heart from worsening.”
The article, “Targeting 5-HT2B Receptor Signaling Prevents Border Zone Expansion and Improves Microstructural Remodeling after Myocardial Infarction,” was published in the journal Circulation on Jan. 21.
Merryman is collaborating with Craig Lindsley, the William K. Warren, Jr. Professor of Medicine, University Professor of Pharmacology, Biochemistry and Chemistry, and director of the Warren Center, to develop a highly targeted molecule that impacts only serotonin 2B in the cardiopulmonary system where the receptor is highly prevalent. The molecule will be designed to not cross the blood brain barrier, thus avoiding neurological side effects. The researchers have conducted three rounds of medicinal chemistry and are reviewing the molecule’s efficacy.
“This molecule has the possibility to not only treat myocardial infarction, but also high blood pressure in the lungs that is known as pulmonary arterial hypertension,” Merryman said. “We are working with many clinicians to sort out the best path for drug development that we think has significant implications for human health.”
The research for this study was supported by the National Institutes of Health grants R35-HL135790, R01-HL115103, R01-HL133290, R01-HL143074, R01-HL138519, K99-HL146951, F32- HL154596, T32-HL007411, T32-EB021937, the American Heart Association grant 18PRE34060078 and a grant from the Fondation Leducq.
Therapeutic development is being supported by a Vanderbilt Discovery Grant. The Discovery Grant program is designed to serve as a catalyst for significant external funding sources, including from large federal funding agencies such as the National Science Foundation, National Institutes of Health, Department of Defense and more.